Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nantong Lianya/Novast Raises $140 Million for Generics and Extended-Release Drugs

publication date: May 11, 2020

Nantong Lianya Pharma and its parent company, Novast Holdings, raised $140 million in private equity led by Legend Capital. Novast is a generic drug company specializing in hard-to-make products, especially extended-release formulations. It has developed more than 180 innovative and generic drugs for global markets. In the US, Novast has FDA permission to market 40 drugs, including more than 30 hormone and nine extended-release products, many of them with a leading market share. In 2012, Novast partnered with Lilly, building a Nantong manufacturing facility to supply products to China's market. More details....

Share this with colleagues:
<br /


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital